- Home
- ABTS vs CANF Comparison
ABTS vs CANF Comparison
Compare ABTS & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTS | CANF |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 6.7M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ABTS | CANF |
|---|---|---|
| Price | $1.21 | $2.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.5K | ★ 212.7K |
| Earning Date | 10-06-2026 | 09-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.17 |
| 52 Week High | $10.70 | $10.40 |
Technical Indicators
Market Signals| Indicator | ABTS | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 38.34 |
| Support Level | $1.01 | $2.16 |
| Resistance Level | $1.51 | $2.39 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 34.15 | 44.00 |
Price Performance
Historical ComparisonAbout ABTS Abits Group Inc
Abits Group Inc is a bitcoin mining company. The Company operates self-owned and hosted bitcoin mining facilities in Tennessee, United States.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.